Sort by
Items per page

Send to

Choose Destination

Best matches for Pagès C[au]:

[Dermatologic toxicities of immune checkpoint inhibitors]. Sibaud V et al. Ann Dermatol Venereol. (2018)

CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease. Boussicault L et al. Brain. (2016)

[Treatment of patients with brain metastases from a melanoma]. Modesto A et al. Cancer Radiother. (2019)

Search results

Items: 1 to 50 of 145


Treatment of Childhood Acute Myeloid Leukemia in Uruguay: Results of 2 Consecutive Protocols Over 20 Years.

Dufort Y Alvarez G, Castiglioni M, Pagés C, Incoronato A, Simon E, Zuccolo S, Schelotto M, Morosini F, Amarillo P, Pereira I, Giordano H, Dabezies A, Castillo L.

J Pediatr Hematol Oncol. 2020 Feb 14. doi: 10.1097/MPH.0000000000001751. [Epub ahead of print]


Multiple Keratoacanthoma-like Lesions in a Patient Treated with Pembrolizumab.

Fradet M, Sibaud V, Tournier E, Lamant L, Boulinguez S, Brun A, Pages C, Meyer N.

Acta Derm Venereol. 2019 Dec 1;99(13):1301-1302. doi: 10.2340/00015555-3301. No abstract available.


Advanced Cutaneous Squamous Cell Carcinoma Is Associated with Suboptimal Initial Management in a Cohort of 109 Patients.

Deilhes F, Boulinguez S, Pagès C, Paul C, Meyer N.

Dermatology. 2019;235(6):516-521. doi: 10.1159/000500636. Epub 2019 Aug 6.


Discoidin domain receptors: A promising target in melanoma.

Reger de Moura C, Battistella M, Sohail A, Caudron A, Feugeas JP, Podgorniak MP, Pages C, Mazouz Dorval S, Marco O, Menashi S, Fridman R, Lebbé C, Mourah S, Jouenne F.

Pigment Cell Melanoma Res. 2019 Sep;32(5):697-707. doi: 10.1111/pcmr.12809. Epub 2019 Jul 22.


Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC).

Lebbe C, Garbe C, Stratigos AJ, Harwood C, Peris K, Marmol VD, Malvehy J, Zalaudek I, Hoeller C, Dummer R, Forsea AM, Kandolf-Sekulovic L, Olah J, Arenberger P, Bylaite-Bucinskiene M, Vieira R, Middleton M, Levy A, Eggermont AM, Battistella M, Spano JP, Grob JJ, Pages C; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organisation for Research and Treatment of Cancer (EORTC).

Eur J Cancer. 2019 Jun;114:117-127. doi: 10.1016/j.ejca.2018.12.036. Epub 2019 May 13.


Severe gastrointestinal toxicity of MEK inhibitors.

Mourad N, Lourenço N, Delyon J, Eftekhari P, Bertheau P, Allayous C, Ballon A, Pagès C, Allez M, Lebbé C, Baroudjian B; PATIO group.

Melanoma Res. 2019 Oct;29(5):556-559. doi: 10.1097/CMR.0000000000000618.


Microscale light management and inherent optical properties of intact corals studied with optical coherence tomography.

Wangpraseurt D, Jacques S, Lyndby N, Holm JB, Pages CF, Kühl M.

J R Soc Interface. 2019 Feb 28;16(151):20180567. doi: 10.1098/rsif.2018.0567.


[Treatment of patients with brain metastases from a melanoma].

Modesto A, Chira C, Sol JC, Lubrano V, Boulinguez S, Pagès C, Sibaud V, Gomez-Roca C, Moyal É, Meyer N.

Cancer Radiother. 2019 Apr;23(2):147-150. doi: 10.1016/j.canrad.2018.05.006. Epub 2019 Mar 21. Review. French.


Osteopenia and fractures associated with long-term therapy with MEK inhibitors.

Dumas M, Laly P, Gottlieb J, Vercellino L, Paycha F, Bagot M, Baroudjian B, Madelaine I, Basset-Seguin N, Eftekhari P, Pagès C, Lebbé C, Lioté F.

Melanoma Res. 2018 Dec;28(6):641-644. doi: 10.1097/CMR.0000000000000490.


Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study.

Gauci ML, Boudou P, Baroudjian B, Vidal-Trecan T, Da Meda L, Madelaine-Chambrin I, Basset-Seguin N, Bagot M, Pages C, Mourah S, Resche-Rigon M, Pinel S, Sassier M, Rouby F, Eftekhari P, Lebbé C, Gautier JF.

Cancer Immunol Immunother. 2018 Aug;67(8):1197-1208. doi: 10.1007/s00262-018-2178-0. Epub 2018 May 28.


Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?

Gauci ML, Baroudjian B, Zeboulon C, Pages C, Poté N, Roux O, Bouattour M, Lebbé C; PATIO group.

J Hepatol. 2018 Aug;69(2):548-550. doi: 10.1016/j.jhep.2018.03.034. Epub 2018 May 7. No abstract available.


[Dermatologic toxicities of immune checkpoint inhibitors].

Sibaud V, Boulinguez S, Pagès C, Riffaud L, Lamant L, Chira C, Boyrie S, Vigarios E, Tournier E, Meyer N.

Ann Dermatol Venereol. 2018 May;145(5):313-330. doi: 10.1016/j.annder.2018.01.047. Epub 2018 Apr 18. Review. French.


Sentinel Lymph Node Biopsy in Cutaneous Squamous Cell Carcinoma Series of 37 Cases and Systematic Review of the Literature.

Lhote R, Lambert J, Lejeune J, Gottlieb J, Badaoui A, Battistella M, Roux J, Pages C, Vercellino L, Vilmer C, Le Maignan C, Escande C, MBarek B, Bagot M, Lebbé C, Basset-Seguin N.

Acta Derm Venereol. 2018 Jul 11;98(7):671-676. doi: 10.2340/00015555-2942. Review.


[Furosemide induced agranulocytosis in heart failure, what else?]

Pages C, Schambach S, Noblet D, Thompson MA, Sirvain S, Fraisse T.

Presse Med. 2017 Nov;46(11):1115-1117. doi: 10.1016/j.lpm.2017.06.016. Epub 2017 Oct 27. French. No abstract available.


Transient pituitary ACTH-dependent Cushing syndrome caused by an immune checkpoint inhibitor combination.

Lupu J, Pages C, Laly P, Delyon J, Laloi M, Petit A, Basset-Seguin N, Oueslati I, Zagdanski AM, Young J, Bouche C, Lebbé C, Gautier JF.

Melanoma Res. 2017 Dec;27(6):649-652. doi: 10.1097/CMR.0000000000000405.


Survival After Fulminant Myocarditis Induced by Immune-Checkpoint Inhibitors.

Arangalage D, Delyon J, Lermuzeaux M, Ekpe K, Ederhy S, Pages C, Lebbé C.

Ann Intern Med. 2017 Nov 7;167(9):683-684. doi: 10.7326/L17-0396. Epub 2017 Sep 5. No abstract available.


Clinical value of early detection of circulating tumour DNA-BRAFV600mut in patients with metastatic melanoma treated with a BRAF inhibitor.

Louveau B, Tost J, Mauger F, Sadoux A, Podgorniak MP, How-Kit A, Pages C, Roux J, Da Meda L, Lebbe C, Mourah S.

ESMO Open. 2017 Jun 21;2(2):e000173. doi: 10.1136/esmoopen-2017-000173. eCollection 2017. No abstract available.


Focal necrotizing myopathy with 'dropped-head syndrome' induced by cobimetinib in metastatic melanoma.

Gauci ML, Laly P, Leonard-Louis S, Behin A, Gottlieb J, Madelaine-Chambrin I, Baroudjian B, Da-Meda L, Mourah S, Battistella M, Basset-Seguin N, Bagot M, Pages C, Vercellino L, Maisonobe T, Lebbé C.

Melanoma Res. 2017 Oct;27(5):511-515. doi: 10.1097/CMR.0000000000000377.


Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review.

Gauci ML, Laly P, Vidal-Trecan T, Baroudjian B, Gottlieb J, Madjlessi-Ezra N, Da Meda L, Madelaine-Chambrin I, Bagot M, Basset-Seguin N, Pages C, Mourah S, Boudou P, Lebbé C, Gautier JF.

Cancer Immunol Immunother. 2017 Nov;66(11):1399-1410. doi: 10.1007/s00262-017-2033-8. Epub 2017 Jun 20. Review.


Sebaceous Carcinomas of the Skin: 24 Cases and a Literature Review.

Haber R, Battistella M, Pages C, Bagot M, Lebbe C, Basset-Seguin N.

Acta Derm Venereol. 2017 Aug 31;97(8):959-961. doi: 10.2340/00015555-2685. Review. No abstract available.


Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab.

Gauci ML, Baroudjian B, Laly P, Madelaine I, Da Meda L, Vercellino L, Bagot M, Lioté F, Pages C, Lebbé C.

Semin Arthritis Rheum. 2017 Oct;47(2):281-287. doi: 10.1016/j.semarthrit.2017.03.003. Epub 2017 Mar 8.


Immunothérapie et mélanome : l’exemple des anticorps immunomodulateurs.

Pagès C, Baroudjian B, Lebbé C.

Bull Cancer. 2016 Nov;103 Suppl 1:S132-S137. doi: 10.1016/S0007-4551(16)30370-8. French.


Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab immunotherapy: observational study of 39 patients.

Amode R, Baroudjian B, Kowal A, Jebali M, Allayous C, Bagot M, Madjlessi N, Roux J, Viguier M, Basset Seguin N, Porcher R, Pagès C, Lebbé C.

Melanoma Res. 2017 Apr;27(2):110-115. doi: 10.1097/CMR.0000000000000313.


Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy.

Felix J, Cassinat B, Porcher R, Schlageter MH, Maubec E, Pages C, Baroudjian B, Homyrda L, Boukouaci W, Tamouza R, Bagot M, Caignard A, Toubert A, Lebbé C, Moins-Teisserenc H.

Int Immunopharmacol. 2016 Nov;40:466-473. doi: 10.1016/j.intimp.2016.09.030. Epub 2016 Oct 8.


Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response.

Felix J, Lambert J, Roelens M, Maubec E, Guermouche H, Pages C, Sidina I, Cordeiro DJ, Maki G, Chasset F, Porcher R, Bagot M, Caignard A, Toubert A, Lebbé C, Moins-Teisserenc H.

Oncoimmunology. 2016 Feb 18;5(7):1136045. doi: 10.1080/2162402X.2015.1136045. eCollection 2016 Jul.


Activity-Regulated Cytoskeleton-Associated Protein Accumulates in the Nucleus in Response to Cocaine and Acts as a Brake on Chromatin Remodeling and Long-Term Behavioral Alterations.

Salery M, Dos Santos M, Saint-Jour E, Moumné L, Pagès C, Kappès V, Parnaudeau S, Caboche J, Vanhoutte P.

Biol Psychiatry. 2017 Apr 1;81(7):573-584. doi: 10.1016/j.biopsych.2016.05.025. Epub 2016 Jun 16.


Sustained response to salvage therapy for dabrafenib-resistant metastatic Langerhans cell sarcoma.

Lorillon G, Mourah S, Vercellino L, de Margerie-Mellon C, Pagès C, Goldwirt L, Lebbe C, Tost J, Tazi A.

Ann Oncol. 2016 Dec;27(12):2305-2307. doi: 10.1093/annonc/mdw299. Epub 2016 Aug 8. No abstract available.


FtsK translocation permits discrimination between an endogenous and an imported Xer/dif recombination complex.

Fournes F, Crozat E, Pages C, Tardin C, Salomé L, Cornet F, Rousseau P.

Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):7882-7. doi: 10.1073/pnas.1523178113. Epub 2016 Jun 17.


Extra Molting and Selection on Nymphal Growth in the Desert Locust.

Pélissié B, Piou C, Jourdan-Pineau H, Pagès C, Blondin L, Chapuis MP.

PLoS One. 2016 May 26;11(5):e0155736. doi: 10.1371/journal.pone.0155736. eCollection 2016.


Mapping Topoisomerase IV Binding and Activity Sites on the E. coli Genome.

El Sayyed H, Le Chat L, Lebailly E, Vickridge E, Pages C, Cornet F, Cosentino Lagomarsino M, Espéli O.

PLoS Genet. 2016 May 12;12(5):e1006025. doi: 10.1371/journal.pgen.1006025. eCollection 2016 May.


Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma.

Danlos FX, Pagès C, Baroudjian B, Vercellino L, Battistella M, Mimoun M, Jebali M, Bagot M, Tazi A, Lebbé C.

Chest. 2016 May;149(5):e133-6. doi: 10.1016/j.chest.2015.10.082.


EMMPRIN/CD147 is an independent prognostic biomarker in cutaneous melanoma.

Caudron A, Battistella M, Feugeas JP, Pages C, Basset-Seguin N, Mazouz Dorval S, Funck Brentano E, Sadoux A, Podgorniak MP, Menashi S, Janin A, Lebbé C, Mourah S.

Exp Dermatol. 2016 Aug;25(8):618-22. doi: 10.1111/exd.13022. Epub 2016 May 20.


Anti-PD1-induced collagenous colitis in a melanoma patient.

Baroudjian B, Lourenco N, Pagès C, Chami I, Maillet M, Bertheau P, Bagot M, Gornet JM, Lebbé C, Allez M.

Melanoma Res. 2016 Jun;26(3):308-11. doi: 10.1097/CMR.0000000000000252.


[Melanoma, from diagnosis to treatment].

Baroudjian B, Pagès C, Lebbé C.

Rev Infirm. 2016 Mar;(219):16-8. doi: 10.1016/j.revinf.2015.12.022. Review. French.


Mechanisms Underpinning Increased Plasma Creatinine Levels in Patients Receiving Vemurafenib for Advanced Melanoma.

Hurabielle C, Pillebout E, Stehlé T, Pagès C, Roux J, Schneider P, Chevret S, Chaffaut C, Boutten A, Mourah S, Basset-Seguin N, Vidal-Petiot E, Lebbé C, Flamant M.

PLoS One. 2016 Mar 1;11(3):e0149873. doi: 10.1371/journal.pone.0149873. eCollection 2016.


CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease.

Boussicault L, Alves S, Lamazière A, Planques A, Heck N, Moumné L, Despres G, Bolte S, Hu A, Pagès C, Galvan L, Piguet F, Aubourg P, Cartier N, Caboche J, Betuing S.

Brain. 2016 Mar;139(Pt 3):953-70. doi: 10.1093/brain/awv384. Epub 2016 Jan 29.


Association of Vemurafenib and Pipobroman Enhances BRAF-CRAF Dimerization in Squamous Cell Carcinoma.

Cassius C, Pages C, Roux J, Lhote R, Lavocat R, Réa D, Bagot M, Mourah S, Battistella M, Lebbé C, Dumaz N.

J Invest Dermatol. 2016 Jun;136(6):1302-1305. doi: 10.1016/j.jid.2015.12.047. Epub 2016 Feb 15. No abstract available.


Reply to 'Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance' by Funck-Brentano et al.

Goldwirt L, Chami I, Feugeas JP, Pages C, Brunet-Possenti F, Allayous C, Baroudjian B, Madelaine I, Sauvageon H, Mourah S, Lebbé C.

Ann Oncol. 2016 Feb;27(2):363-4. doi: 10.1093/annonc/mdv538. Epub 2015 Nov 16. No abstract available.


Dramatic transient improvement of metastatic BRAF(V600E)-mutated Langerhans cell sarcoma under treatment with dabrafenib.

Mourah S, Lorillon G, Meignin V, Vercellino L, de Margerie-Mellon C, Pages C, Goldwirt L, How-Kit A, Tost J, Lebbe C, Tazi A.

Blood. 2015 Dec 10;126(24):2649-52. doi: 10.1182/blood-2015-06-650036. Epub 2015 Oct 14. No abstract available.


BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma.

Roux J, Pages C, Malouf D, Basset Seguin N, Madjlessi N, Baccard M, Comte C, Archimbaud A, Battistella M, Viguier M, Mourah S, Bagot M, Lebbe C.

Melanoma Res. 2015 Dec;25(6):559-63. doi: 10.1097/CMR.0000000000000196.


Ultrasound-guided core needle biopsy of superficial lymph nodes: an alternative to fine-needle aspiration cytology for the diagnosis of lymph node metastasis in cutaneous melanoma.

Bohelay G, Battistella M, Pagès C, de Margerie-Mellon C, Basset-Seguin N, Viguier M, Kerob D, Madjlessi N, Baccard M, Archimbaud A, Comte C, Mourah S, Porcher R, Bagot M, Janin A, De Kerviler E, Lebbé C.

Melanoma Res. 2015 Dec;25(6):519-27. doi: 10.1097/CMR.0000000000000161.


Sentinel node status and immunosuppression: recurrence factors in localized Merkel cell carcinoma.

Jouary T, Kubica E, Dalle S, Pages C, Duval-Modeste AB, Guillot B, Mansard S, Saiag P, Aubin F, Bedane C, Dalac S, Dompmartin A, Granel-Brocard F, Lok C, Stoebner PE, Lacour JP, Leccia MT, Diallo A, Ezzedine K, Mateus C.

Acta Derm Venereol. 2015 Sep;95(7):835-40. doi: 10.2340/00015555-2099.


[Targeted molecular therapies (except immunotherapy)].

Roux J, Pages C, Lebbé C.

Bull Cancer. 2014 Dec;101 Suppl 2:S25-36. doi: 10.1684/bdc.2014.2053. Review. French.


Tissue-engineered oral mucosa grafts for intraoral lining reconstruction of the maxilla and mandible with a fibula flap.

Sieira Gil R, Pagés CM, Díez EG, Llames S, Fuertes AF, Vilagran JL.

J Oral Maxillofac Surg. 2015 Jan;73(1):195.e1-16. doi: 10.1016/j.joms.2014.09.001. Epub 2014 Sep 16.


Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids.

Chasset F, Pages C, Biard L, Roux J, Sidina I, Madelaine I, Basset-Seguin N, Viguier M, Madjlessi-EzrA N, Schneider P, Bagot M, Resche-Rigon M, Lebbe C.

Eur J Dermatol. 2015 Jan-Feb;25(1):36-44. doi: 10.1684/ejd.2014.2471.


Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma.

Danlos FX, Pagès C, Roux J, Jebali M, Gornet JM, Bagot M, Lebbé C.

Melanoma Res. 2015 Apr;25(2):178-9. doi: 10.1097/CMR.0000000000000132.


Soluble VEGFR-1: a new biomarker of sorafenib-related hypertension (i.e., sorafenib-related is the compound adjective?).

Thomas-Schoemann A, Blanchet B, Boudou-Rouquette P, Golmard JL, Noé G, Chenevier-Gobeaux C, Lebbe C, Pages C, Durand JP, Alexandre J, Goldwasser F, Guibourdenche J, Vidal M.

J Clin Pharmacol. 2015 Apr;55(4):478-9. doi: 10.1002/jcph.429. Epub 2014 Dec 30. No abstract available.


Surgical planning and microvascular reconstruction of the mandible with a fibular flap using computer-aided design, rapid prototype modelling, and precontoured titanium reconstruction plates: a prospective study.

Sieira Gil R, Roig AM, Obispo CA, Morla A, Pagès CM, Perez JL.

Br J Oral Maxillofac Surg. 2015 Jan;53(1):49-53. doi: 10.1016/j.bjoms.2014.09.015. Epub 2014 Oct 8.


BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.

Lebbé C, How-Kit A, Battistella M, Sadoux A, Podgorniak MP, Sidina I, Pages C, Roux J, Porcher R, Tost J, Mourah S.

Melanoma Res. 2014 Aug;24(4):415-8. doi: 10.1097/CMR.0000000000000088. No abstract available.


Four cases of rituximab-associated melanoma.

Velter C, Pagès C, Schneider P, Osio A, Brice P, Lebbé C.

Melanoma Res. 2014 Aug;24(4):401-3. doi: 10.1097/CMR.0000000000000074.


Supplemental Content

Support Center